Press release from Companies: Mount Sinai Hospital in New York joins RhoVac’s Phase IIb Study in Prostate Cancer

Press release from Companies: Mount Sinai Hospital i New York ansluter sig till RhoVacs fas IIb-studie i prostatacancer

Press release from Companies: Kallelse till årsstämma i RhoVac AB

Press release from Companies: Den globala utrullningen av Covid-19 Vaccinering försenar RhoVacs fas IIb-studie

Press release from Companies: Global Covid-19 Vaccination Roll-out causes delay to RhoVac’s Phase IIb study

Reports: RhoVac AB offentliggör bokslutskommuniké för verksamhetsåret 2020

Press release from Companies: First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

Press release from Companies: Första patienten i behandling i RhoVacs kliniska fas IIb-studie i Storbritannien

Press release from Companies: RhoVac’s Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Press release from Companies: RhoVacs läkemedelskandidat för prostatacancer, RV001, beviljas Fast Track Designation av FDA

Press release from Companies: Komplettering: Positiva Resultat från RhoVacs kliniska fas I/II-studie publicerade i Journal for ImmunoTherapy of Cancer

Press release from Companies: Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer